On May 21, the U.S. Senate’s Permanent Subcommittee on Investigations held a crucial hearing titled "The Corruption of ...

Research shows RSV leads to high hospitalization rates in adults, emphasizing the importance of enhanced surveillance and ...

BioNTech has announced the acquisition of fellow German biotech CureVac in an all-stock transaction valued at approximately ...

Opportunities in healthcare cold chain logistics include the rise in demand for biologics and personalized medicines, driven ...

Moderna, Inc. (NASDAQ:MRNA – Get Free Report) has been given an average rating of “Hold” by the twenty-three analysts that ...

COVID-19 has largely dropped out of the headlines, but the virus that causes it is still circulating. We ask what we should know about a new variant of SARS-CoV-2, the state of the COVID-19 pandemic ...

Some of the market’s most expensive stocks are also its weakest earners, bleeding losses despite lofty valuations. For ...

This news roundup covers significant developments in the health industry, including France's Carmat filing for insolvency, ...

Amid promising signs, officials urged caution, noting that the outbreaks vary by clade, response measures, and social ...

Moderna today reported promising relative vaccine efficacy (rVE) findings from a phase 3 trial of its seasonal mRNA flu ...

Astonishing claims have emerged from recent studies suggesting a chilling surge in cancer rates, particularly among women, reportedly linked to climate change. However, the narrative being pushed by ...

The global microfluidics market, valued at approximately USD 28.65 billion in 2022, is poised for robust growth, with a projected compound annual growth rate (CAGR) of over 12.22% from 2023 to 2030.